carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont]
carbidopa
RxCUI: 2690265
What the CMS Formulary Data Shows for carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont]
Per the CMS 2026 Part D formulary file, carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] (RxNorm concept RXCUI 2690265, generic name carbidopa) appears on 4 distinct formulary files spanning 6 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.5.
Real-world access to carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 4,842 Part D beneficiaries filled carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] in 2023, with total plan-and-beneficiary spending of $8,630,589 and an average per-beneficiary annual cost of $1,782.44. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] today.
Coverage Details
- Formularies covering
- 4
- Plans covering
- 6
- Coverage rate
- 0.1%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 4,842
- Total spending
- $8,630,589
- Avg per beneficiary
- $1,782.44
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont]
6 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Mass General Brigham SCO (HMO D-SNP) | MASS GENERAL BRIGHAM HEALTH PLAN, INC | T1 | No | $0 | MA |
| Mass General Brigham One Care (HMO D-SNP) | MASS GENERAL BRIGHAM HEALTH PLAN, INC | T1 | No | $0 | MA |
| Mass General Brigham Advantage (PPO) | Mass General Brigham Health Plan, Inc. | T4 | No | $0 | MA |
| Mass General Brigham Advantage Secure (HMO-POS) | Mass General Brigham Health Plan, Inc. | T4 | No | $62.00 | MA |
| Mass General Brigham Advantage Premier (PPO) | Mass General Brigham Health Plan, Inc. | T4 | No | $79.70 | MA |
| Mass General Brigham Advantage Signature (PPO) | Mass General Brigham Health Plan, Inc. | T4 | No | $147.20 | MA |
Frequently Asked Questions
Is carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] covered by Medicare Part D?
Yes, carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] is covered by 6 Medicare Part D plans (0.1% of all Part D formularies).
What tier is carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] on Medicare Part D plans?
carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] averages Tier 2.5 across Part D plans, ranging from Tier 1 to Tier 4.
Does carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] require prior authorization?
0% of Part D formularies require prior authorization for carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont]?
In 2023, total Medicare Part D spending on carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] was $8,630,589, covering 4,842 beneficiaries. The average spend per beneficiary was $1,782.44.
Read our methodology - how this data is sourced, computed, and verified.